Postmarketing Surveillance Methodologies
- 1 January 1988
- journal article
- review article
- Published by SAGE Publications in Drug Intelligence & Clinical Pharmacy
- Vol. 22 (1), 68-78
- https://doi.org/10.1177/106002808802200117
Abstract
This article describes and discusses the strengths and limitations of the major pharmacoepidemiologic methodologies employed in postmarketing drug surveillance and describes the current status of the U.S. surveillance system. The main methodologies employed in postmarketing drug surveillance include controlled clinical trials, observational epidemiologic studies (cohort, case-control, cross-sectional), demographic methods, drug utilization surveys, spontaneous reports, and automated databases linking medications and disease. Examples of pharmacoepidemiologic studies using each of these methodologies are presented. When a question arises about the efficacy and/or safety of a marketed drug, typically a mixture of these study methodologies is employed. The article concludes with a brief discussion of the role of the Food and Drug Administration, pharmaceutical manufacturers, and academic institutions in initiating and conducting postmarketing drug studies.Keywords
This publication has 51 references indexed in Scilit:
- Drug Utilization Study Methodologies: National and International PerspectivesDrug Intelligence & Clinical Pharmacy, 1987
- The Drug Approval Process and the Information it ProvidesDrug Intelligence & Clinical Pharmacy, 1987
- The Contribution of Epidemiology to the Study of DrugsDrug Intelligence & Clinical Pharmacy, 1987
- The Will Rogers PhenomenonNew England Journal of Medicine, 1985
- Identification of adverse reactions to new drugs. II (continued): How were 18 important adverse reactions discovered and with what delays?BMJ, 1983
- Identification of adverse reactions to new drugs. II--How were 18 important adverse reactions discovered and with what delays?BMJ, 1983
- Identification of adverse reactions to new drugs. I: What have been the important adverse reactions since thalidomide?BMJ, 1983
- Postmarketing Surveillance of New Drugs: I. Review of Objectives and MethodologyThe Journal of Clinical Pharmacology, 1979
- Drug Evaluation After MarketingAnnals of Internal Medicine, 1979
- Panel 4: Phase IV investigationsClinical Pharmacology & Therapeutics, 1975